




# INVESTING IN INNOVATIVE DUTCH LIFE SCIENCES FACILITIES

- **Mibiton Science** finances equipment for spin-off companies still incubating on the premises of a research organization. Investments of up to € 200,000 are shared with a research department.
- **Mibiton Solo** provides loans of up to € 400,000 to acquire equipment for young Life Sciences companies.
- **Mibiton Share** facilities are exploited by at least two partners, one of which is a Life Sciences SME. Investments may accumulate to up to € 600,000.



STEFAN BRAAM, CEO NCARDIA:

“MIBITON ENABLED THE ACQUISITION OF A STATE-OF-THE-ART BIOREACTOR SYSTEM FOR THE CULTIVATION OF HIGH QUALITY hiPSC-DERIVED CELLS. THIS BIOREACTOR IS ESSENTIAL IN ORDER TO OPTIMIZE OUR PROCESS DEVELOPMENT TOWARDS INDUSTRIAL SCALE MANUFACTURING. THE MIBITON INVESTMENT ALSO SUPPORTS ALL STAGES OF OUR STEM CELL-BASED DRUG DISCOVERY AND DEVELOPMENT PROGRAMS.”

**Ncardia BV Leiden, the Netherlands**  
[www.ncardia.com](http://www.ncardia.com)

**Ncardia** is a stem cell drug discovery and development company. We believe that stem cell technology can bring safe and better medicines to patients faster. At Ncardia we combine our cardiovascular knowledge with expertise on hiPSC-derived cardiomyocyte manufacturing to offer predictive and translational *in vitro* (disease) models and assays for safety and efficacy screening. To implement hiPSC-derived cardiomyocytes at every stage of drug discovery and development, manufacturing of large batches of human cardiomyocytes with low batch-to-batch variation is key. We employ state-of-the-art bioreactor systems for the cultivation of high quality hiPSC-derived cardiomyocytes. The combination of these systems with our proprietary differentiation protocols allows us to offer a fast and robust industrial-scale manufacturing of the hiPSC-derived cells of interest.

[WWW.MIBITON.NL](http://WWW.MIBITON.NL)